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OBJECTIVE—The metabolic outcome of islet cell transplants
in type 1 diabetic patients is variable. This retrospective analysis
examines whether differences in recipient characteristics at the
time of transplantation are correlated with inadequate graft
function.
RESEARCH DESIGN AND METHODS—Thirty nonuremic
C-peptide–negative type 1 diabetic patients had received an
intraportal islet cell graft of comparable size under an ATG-
tacrolimus–mycophenolate mofetil regimen. Baseline patient
characteristics were compared with outcome parameters during
the ﬁrst 6 posttransplant months (i.e., plasma C-peptide, glyce-
mic variability, and gain of insulin independence). Correlations in
univariate analysis were further examined in a multivariate
model.
RESULTS—Patients that did not become insulin independent
exhibited signiﬁcantly higher counts of B-cells as well as a T-cell
autoreactivity against insulinoma-associated protein 2 (IA2)
and/or GAD. In one of them, a liver biopsy during posttransplant
year 2 showed B-cell accumulations near insulin-positive -cell
aggregates. Higher baseline total lymphocytes and T-cell autore-
activity were also correlated with lower plasma C-peptide levels
and higher glycemic variability.
CONCLUSIONS—Higher total and B-cell counts and presence
of T-cell autoreactivity at baseline are independently associated
with lower graft function in type 1 diabetic patients receiv-
ing intraportal islet cells under ATG-tacrolimus–mycophenolate
mofetil therapy. Prospective studies are needed to assess whether
control of these characteristics can help increase the function of
islet cell grafts during the ﬁrst year posttransplantation. Diabetes
58:2267–2276, 2009
I
slet cell tranplantation is a promising therapy for
type 1 diabetic patients, but its current state faces
several limitations and obstacles (1,2). Insulin inde-
pendence can be achieved during the ﬁrst year
posttransplantation in up to 80% of selected patients in
small, single-center cohorts (3–7), but the success rate is
lower in larger studies with less stringent criteria for
selection of recipients and donor tissue (8,9). Several
factors can account for the observed variability in out-
come. Their identiﬁcation is hindered by the difﬁculty in
standardizing protocols and by the small numbers of
patients that have so far been included per protocol.
Within these limitations, graft and recipient characteristics
have been related with the outcome of clinical islet cell
transplantation (10–13). A minimal donor tissue mass was
reported to induce insulin independence but is in itself not
sufﬁcient (3,10,13); administration of more potent immune
suppressants can lower this treshold (14,15), which is
lowest in autologous transplantation (16). Using cultured
-cell preparations in an ATG-based protocol, we deﬁned
the minimal number of -cells that reproducibly resulted
in circulating signs of a surviving graft 2 months after
transplantation (17). In the latter study, achievement of
insulin independence also depended on the -cell mass in
the graft but appeared counteracted by the presence of an
islet-speciﬁc T-cell autoreactivity as measured by in vitro
lymphocyte stimulation tests against the islet autoantigens
GAD and insulinoma-associated protein 2 (IA2) (18). We
have now analyzed a cohort of 30 consecutively trans-
planted recipients in search for a possible correlation
between their baseline characteristics and the clinical
outcome of deﬁned islet cell grafts that are intraportally
injected under the same ATG-based protocol.
RESEARCH DESIGN AND METHODS
Graft recipients and baseline characteristics. Between September 2000
and January 2006, 35 nonuremic type 1 diabetic patients received an islet cell
transplant under ATG induction therapy and maintenance immune suppres-
sion with mycophenolate mofetil (MMF) and tacrolimus. They were all
C-peptide negative, had large within-subject variation of fasted glycemia
(coefﬁcient of variation of prebreakfast glycemia [CVfg] 25%), and one or
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diabetes.diabetesjournals.org DIABETES, VOL. 58, OCTOBER 2009 2267more signs of diabetic lesions (hypoglycemic unawareness, microalbuminuria,
or retinopathy). The ﬁrst 24 patients had been included in a phase 1 graft-dose
ﬁnding study and the last 11 patients in a protocol that aims to assess
inﬂuence of tapering of tacrolimus after month 12. Graft survival with this
immune-suppressive regimen was previously reported for the ﬁrst 24 patients
(17,18). Informed consent had been obtained from all candidate recipients
before they were listed as such by the Eurotransplant Foundation. Selection
for transplantation occurred on basis of listing date, bloodgroup compatibility
with the available graft, and health status. At the time of transplantation, none
presented symptoms of acute infectious disease or inﬂammation. Analysis for
cytomegalovirus (PCR and serology) and hepatitis A, B, and C (serology) at
baselineexcludedactivedisease.Twopatientstestedpositiveforcomplement-
binding HLA antibodies pretransplantation, two patients that discontinued
immune suppression during the ﬁrst 6 months and one patient that died from
a cerebral hemoraghe at 18 weeks posttransplant. These ﬁve patients were
excluded from the current analysis.
Graft characteristics and transplantation procedure. Islet cells were
isolated and cultured according to standardized protocols (17,19,20). For all
islet cell grafts used, a sample was taken before transplantation and analyzed
for its insulin synthesis capacity in the absence and presence of glucose (10
mmol/l). They all fulﬁlled the set criteria for function (i.e., minimally 20 pmol
insulin synthesized per 2 h per million -cells). Preparations were analyzed for
their cellular composition and combined to grafts before being infused into the
portal vein using either a laparoscopic (n  16) (21) or subcutaneous transhe-
patic approach (n  14) (22). Donor and graft characteristics are listed in
appendix 1 (available at http://diabetes.diabetesjournals.org/cgi/content/
full/db09-0160/DC1).
Immune and anticoagulant therapy. Induction therapy consisted of rabbit
ATG (Fresenius HemoCare, Redmond, WA) initiated 1–4 days before trans-
plantation. A ﬁrst dose of 9 mg/kg body wt was followed by 3 mg/kg for 6 days;
no injection was given on days with a T-cell count 50 cells/mm
3. Mainte-
nance immunesuppression consisted of MMF (2,000 mg/day Cellcept starting
on the day of the ﬁrst ATG injection; gift of Roche, Brussels, Belgium) and
tacrolimus (Prograft, starting 1 day before the last ATG injection, Fujisawa).
Tacrolimus troughlevels were maintained between 8 and 10 ng/ml during the
ﬁrst 3 months after an islet cell transplantation and 6–8 ng/ml thereafter. This
MMF-tacrolimus treatment was continued when a second islet cell transplant
was given, without additional antibody course, but with one injection of 500
mg methylprednisolone 3 h before transplantation. Anticoagulant therapy was
started 1 day after infusion and consisted of acetylsalycilic acid 100 mg once
daily in all patients and additional low–molecular weight heparin at preventive
dosage in 18 subjects (0.3 ml Fraxiparin once daily). No heparin was
administered during islet infusion.
Assessment of baseline characteristics and transplantation outcome.
Efﬁcacy and safety criteria were examined weekly during the ﬁrst 6 weeks
posttransplant, every 2 weeks between posttransplant week 6 and 12, and
monthly thereafter. The CVfg was assessed using home glucose monitoring.
Plasma C-peptide (TRFIA; Perkin-Elmer, Turku, Finland) with corresponding
glycemia, A1C levels (HPLC; Pharmacia Biotech, Upsala, Sweden), and
autoantibodies [islet cell antibody, IA2A, GAD antibody, and I(A)A] were
assayed in the central laboratory of the Belgian Diabetes Registry (23). There
was also a central measurement of lymphocyte subsets CD3, CD4, CD8,
CD19, and NK cells (CD3CD16CD56) (EpicsXl ﬂow cytometer; Beck-
man Coulter, Miami, FL). Total lymphocyte counts were determined by
routine hematology in local centers. Baseline characteristics of graft recipi-
ents are shown in online appendix 1. The majority of patients (n  24) were
treated with a subcutaneous insulin pump for at least 2 months prior to
transplantation. In one patient, insulin pump was started in the second week
after ﬁrst islet infusion. Insulin tapering was only considered in patients with
plasma C-peptide values 1.0 ng/ml (at glycemia 120–220 mg/dl), CVfg 25%,
and mean fasting glycemia 125 mg/dl and was started after month 2 at a rate
of 2 IU every 3–5 days or faster when patients experienced hypoglycemic
episodes (70 mg/dl).
Lymphocyte stimulation test to determine baseline autoreactivity
against islet cell antigens. Baseline T-cell autoreactivity to islet cell
antigens was assessed at the Leiden University Medical Center and data
analyzed blinded from clinical outcome. Blood was drawn before the ﬁrst ATG
administration, and peripheral blood mononuclear cells were isolated and
processed as described before (24). Brieﬂy, 150,000 fresh peripheral blood
mononuclear cells were cultured in triplicate in 96-well round-bottomed
plates in Iscove’s modiﬁed Dulbecco’s medium with 2 mmol/l glutamine (Life
Technologies, Paisley, Scotland) and 10% pooled human serum in presence of
islet autoantigens IA-2 (10 g/ml) or GAD65 (10 g/ml), of interleukin-2 (35
units/ml), or of medium alone. After 5 days,
3H-thymidine (0.5 CI/well) was
added and its incorporation measured after 16 h. Data were expressed as a
stimulation index (Si) by comparison with the medium alone value. An Si 3
for any of the two antigens was considered a sign of T-cell autoreactivity
against an islet cell antigen. In three patients, cellular autoreactivitiy could not
be assessed because autoantigens were not available for testing of baseline
samples.
Histology. In one patient, a third islet cell preparation was injected at
posttransplant week 60. During the laparoscopically guided infusion, a liver
biopt was taken from a steatotic area on the liver surface. Immunohistochem-
istry was performed on semiconsecutive parafﬁn-embedded sections using a
rabbit insulin antibody (raised by Dr C. Van Schravendijk, Vrije Universiteit
Brussels, Brussels, Belgium) and monoclonal CD3 (NeoMarkers, Freemont,
CA) and CD20 (DAKO, Glostrup, Denmark) antibodies. Human tonsils and
pancreas was used as control. For epitope retrieval, sections were heated to
98°C with citrate buffer, pH 6.0.
Statistics. All values are expressed as median and interquartile range (IQR),
unless indicated otherwise. Baseline and postransplant characteristics were
related with status of insulin independence at month 6 as well as -cell graft
function and glycemic variability during the ﬁrst 6 months. To assess
differences between subgroups, we used nonparametric Mann-Whitney U test
for continuous data and Fisher’s exact test for categorical data. Correlations
between baseline characteristics and CVfg or mean C-peptide during the ﬁrst
6 months after transplantation were assessed by calculating Pearson’s corre-
lation coefﬁcient.
To determine independent predictor ability of the variables, we used
forward stepwise binary logistic regression analysis for insulin independence
and a stepwise linear regression model for both CVfg and mean C-peptide. The
analysis was performed on 27 subjects. Three subjects could not be included
because of missing data. In our multivariate model we included parameters
with P value 0.05 in univariate analysis.
All analysis were performed using SPPS (version 16.0), and graphics were
computed by GraphPad Prism (version 4.0). All reported P values are two
sided, and P  0.05 was considered signiﬁcant.
RESULTS
Metabolic outcome of islet cell transplantation. All 30
recipients became C-peptide positive after transplantation;
1 of them returned to C-peptide negativity before post-
transplant month 6. At posttransplant month 6, 15 patients
were insulin independent while the other 15 were on
TABLE 1
Metabolic outcome 6 months after islet cell transplantation
At posttransplant month 6
P* Insulin independent Insulin dependent
C-peptide positive (n) 15/15 14/15
C-peptide (ng/ml) 2.3 (1.9–3.0) 1.0 (0.4–1.2) 0.001
Fasting glycemia
Mean (mg/dl) 127 (115–135) 132 (127–153) 0.12
CVfg (%) 9 (8–10) 19 (15–39) 0.001
A1C (%) 6.1 (5.8–6.4) 6.1 (5.7–6.7) 0.66
Insulin dose (IU  kg
1  day
1) 0 0.27 (0.20–0.46) 0.001
Percentage of baseline insulin dose (%) 0 43 (34–69) 0.001
Data are medians (IQR). Fasting glycemia was measured at home, and within-subject variation of fasted glycemia (CVfg) was calculated
during the preceding month. *Statistical analysis was done with Mann-Whitney U test.
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similar A1C concentrations and fasting mean glucose
levels (Table 1). However, insulin-independent recipients
had signiﬁcantly higher basal C-peptide levels and exhib-
ited a lower variability of fasting glycemia (Table 1).
Comparison of insulin-independent and insulin-
treated recipients for their baseline graft and recip-
ient characteristics. No differences between both patient
groups were noticed in terms of graft characteristics
(Table 2); respectively, 87 and 80% of their subjects had
received at least 2 milion -cells per kg body wt in the
ﬁrst graft.
Baseline recipient characteristics such as age, sex, body
weight–BMI, duration of disease, autoantibody positivity,
metabolic control, and insulin dose were also similar
(Table 2); a tendency to higher A1C concentrations was
noticed in patients who did not become insulin indepen-
dent (P  0.054). After ﬁrst transplantation, 14 patients
who would achieve insulin independence continued treat-
ment with insulin pump for a median time of 15 weeks
(IQR 10–18). Among patients not achieving insulin inde-
pendence, seven were treated with insulin pump during
the 6-month follow-up. In four patients, insulin pump was
discontinued after a median of 20 weeks because of low
daily insulin need and replaced by subcutanuous injec-
tions four times a day. Metabolic control during the ﬁrst 2
months did not differ between groups with median A1C
values of 5.0% (IQR 4.4–5.9) in insulin-independent sub-
jects vs. 5.2% (IQR 4.7–5.9) in insulin-requiring patients
(P  0.48). The number of patients treated with low–
molecular weight heparin after transplantation did not
differ between groups.
On the other hand, a signiﬁcant difference was observed
in the baseline immune state (before ATG treatment), as
TABLE 2
Graft and recipient characteristics according to insulin need at 6 months posttransplantation
At posttransplant month 6




First graft 3.0 (2.2–4.2) 2.5 (2.0–2.9) 0.16
Total 4.5 (3.5–5.7) 3.7 (2.6–4.7) 0.11
Cellular composition
-Cells 32 (21–38) 30 (20–37) 0.87
-Cell 9 (4–11) 7 (5–10) 0.34
Nongranulated cells 46 (41–63) 45 (34–62) 0.28
Acinar cells 1 (1–4) 1 (1–5) 0.80
Dead cells 8 (6–11) 10 (7–12) 0.31
Two -cell grafts 8 9 1.00
Culture time (days) 6 (4–9) 6 (4–10) 0.66
Recipient
Age (years) 45 (41–49) 40 (32–52) 0.14
Sex (male/female) 10/5 7/8 0.46
Body weight (kg) 68 (64–74) 68 (62–78) 0.72
BMI (kg/m²) 23 (21–26) 25 (22–26) 0.55
Duration of disease (years) 27 (21–33) 24 (17–32) 0.30
A1C (%) 7.0 (6.5–7.9) 7.8 (7.4–8.1) 0.05
Insulin dose (IU  kg
1  day
1) 0.52 (0.39–0.74) 0.67 (0.58–0.85) 0.13
Insulin pump before transplantation 14 10 0.17
Fasting glycemia
Mean (mg/dl) 146 (129–174) 166 (123–199) 0.65
CVfg (%) 43 (38–46) 46 (35–50) 0.42
Immune status before ATG
Total lymphocyte count 1,579 (1,380–1,885) 2,065 (1,869–3,005) 0.007
CD3 count (cells/mm
3) 1,142 (916–1,342) 1,419 (1,160–1,867) 0.049
CD19 count (cells/mm
3) 247 (141–271) 318 (227–514)† 0.023
Leucocyte count 5,300 (4,400–6,000) 6,400 (5,700–8,100) 0.040
Presence of T-cell reactivity against IA2 and/or GAD 6/13 12/14† 0.046
Positivity for ICA/GAD/IA2-A 4/8/6 2/5/7 0.65/0.46/1.0
Positivity for two or more autoantibodies 5 3 0.68
Immune status at ﬁrst infusion
Total lymphocyte count 238 (122–313) 273 (173–748) 0.19
CD3 count (cells/mm
3) 24 (15–43) 36 (9–83) 0.73
Leucocyte count 4,700 (2,900–11,400) 8,300 (3,225–12,225) 0.36
Immune monitoring 0–6 months posttransplant
Presence of T-cell reactivity against IA2 and/or GAD 5/13 8/14 0.45
Positivity for ICA/GAD/IA2-A 4/8/6 2/7/9 0.65/1.0/1.0
De novo HLA-Ab (CDC) 1 1 1.0
Data are medians (IQR). *Statistical analysis was done with Mann-Whitney U test for continues variables, Fisher exact test for dichotomous
variables. †These variables were conﬁrmed as independently associated with insulin independence by multivariate analysis (binary logistic
regression).
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CD3 cells, and of CD19 cells, with higher initial counts
in the recipient group that would not become insulin
independent (Table 2). Of four patients with a baseline
lymphocyte count 3,000 cell/mm
3 (range 3,005–3,455),
none became insulin independent. The higher initial num-
ber of T-cells in the insulin-dependent group was associ-
ated with a higher number of CD8 cells (547/mm
3 [IQR
462–657] vs. 393/mm
3 [305–503] in insulin-independent
patients; P  0.021) but not of CD4 T-cells (850/mm
3
[742–1,134] and 716/mm
3 [570–936], respectively; P  0.093)
or of NK cells (184/mm
3 [147–302] vs. 174/mm
3 [144–271],
respectively; P  0.72). At the day of islet infusion, a simi-
lar tendency was noted (Table 2). B-cell and T-cell autoreac-
tivity were not measured at the day of islet infusion.
At the time of a second infusion (Table 3) we observed
slightly higher CD3 counts in insulin-dependent patients.
It is important to note that in these 17 patients we still
observed a signiﬁcant difference in lymphocyte subsets in
samples taken before ATG administration. There were no
differences in immune proﬁle and reactivity between pa-
tients receiving one or two grafts.
Both groups also differed in their baseline T-cell auto-
reactivity. This in vitro test could be performed in 27 of 30
subjects listed in Table 2. In the group that did not become
insulin independent, 12 of 14 patients scored positive for
IA2 and/or GAD65, whereas this was only the case in 6 of
13 patients who would become insulin independent (P 
0.046; Table 2). The role of baseline T-cell autoreactivity
remained conﬁned to a subgroup of recipients receiving
amounts of -cells below the median, as we previously
reported (18; online appendix 2). On the other hand, no
difference was seen in baseline autoantibody status or in
the presence of multiple autoantibodies prior to transplan-
tation (Table 2). Of 19 patients positive for IA2 and/or
GAD65 antibodies at baseline, 10 became insulin indepen-
dent, whereas this was the case for 5 of 10 patients that
were negative for these antibodies (P  1.0 by Fisher’s
exact test). This was also the case for islet cell antibody
positivity. The number of HLA mismatches did not differ
between groups (data not shown).
Univariate and multivariate analysis of associations
between baseline recipient and graft characteristics
and clinical outcome parameters. The observed corre-
lation between baseline immune status of the recipient
and the achievement of insulin independence at posttrans-
plant month 6 was further examined by multivariate
analysis (Table 4). Baseline B-cell count and T-cell auto-
reactivity were found to be independently correlated with
the ability to achieve insulin independence (odds ratio
0.989 [95% CI 0.979–0.999] and 0.101 [0.009–1.067], respec-
tively). Of nine patients without T-cell autoreactivity at
start, seven became insulin independent, whereas this was
only the case for 6 of 18 patients that tested positively (Fig.
1B). When these patients were further stratiﬁed according
to their baseline B-cell count (i.e., under or above the 50th
percentile [259 B-cells/mm
3]), insulin independence was
seen in seven of eight patients without baseline T-cell
autoreactivity and a B-cell count p50, while only 1 of 11
patients with T-cell autoreactiviy and a B-cell count p50
became insulin independent (P  0.001 by Fisher’s exact
test).
In univariate analysis, similar correlations were found
with other clinical outcome parameters, such as the aver-
age coefﬁcient of variation of prebreakfast glycemia
(CVfg) and the mean plasma C-peptide levels during the
ﬁrst 6 months (Table 4). After multivariate analysis, base-
line positivity for T-cell autoreactivity and total lympho-
cyte counts correlated positively with the values of CVfg
and negatively with the mean C-peptide levels (Fig. 2A). A
TABLE 3
Immune status before ﬁrst and second islet infusion according to insulin need at 6 months posttransplantation among recipients
receiving two islet grafts
At posttransplant month 6
P* Insulin independent Insulin dependent
n 89
Grafts
Immune status before ATG
Total lymphocyte count 1,567 (1,044–2,023) 2,065 (1,906–2,721) 0.03
CD3 count (cells/mm
3) 1,134 (839–1,328) 1,419 (1,189–1,761) 0.07
CD19 count (cells/mm
3) 223 (119–255) 267 (225–430) 0.04
Leucocyte count 5,250 (3,950–6,925) 6,400 (5,700–8,400) 0.08
Presence of T-cell reactivity against IA2 and/or GAD 5/12 7/12 0.57
Positivity for ICA/GAD/IA2-A 3/5/2 1/4/4 NS
Positivity for two or more autoantibodies 3 2 0.62
Immune status at ﬁrst infusion
Total lymphocyte count 189 (97–584) 272 (154–779) 0.25
CD3 count (cells/mm
3) 27 (12–134) 52 (12–80) 1.0
Leucocyte count 3,350 (2,525–7,700) 8,700 (2,725–13,350) 0.29
Immune status before second infusion
Total lymphocyte count 499 (357–593) 636 (501–833) 0.15
CD3 count (cells/mm
3) 186 (169–267) 277 (224–341) 0.05
CD19 count (cells/mm
3) 213 (84–269) 182 (152–311) 0.50
Leucocyte count 3,150 (2,250–3,825) 3,900 (3,300–4,900) 0.08
Presence of T-cell reactivity against IA2 and/or GAD 2 3 0.62
Positivity for ICA/GAD/IA2-A 1/5/2 1/6/4 NS
Positivity for two or more autoantibodies 2 3 0.62
Data are median (IQR). *Statistical analysis was done with Mann-Whitney U test for continues variables, Fisher exact test for dichotomous
variables. NS, not signiﬁcant.
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maintained after multivariate analysis for CVfg but not
C-peptide. Recipients with baseline T-cell reactivity had
signiﬁcantly higher CVfg (24% [IQR 20–35]) and lower
C-peptide (1.0 ng/ml [0.5–1.3]) than those without (18%
[15–24], P  0.014, and 1.9 ng/ml [1.3–2.2; P  0.001],
respectively) (Fig. 2B). These differences became more
pronounced when a further stratiﬁcation was made ac-
cording to presence or absence of a baseline total lympho-
cyte count p50. Thus, a negative test for T-cell
autoreactivity and a lymphocyte count p50 was associ-
ated with a lower CVfg and a higher C-peptide, whereas a
positive test and a count p50 appeared to predispose for
a high CVfg and a low C-peptide (Fig. 2A and B). The
number of -cells transplanted per kilogram bodyweight in
the ﬁrst graft had a tendency to correlate with CVfg in
univariate analysis (R  0.34; P  0.07) but not with
C-peptide levels during the ﬁrst 6 months posttransplant
(R  0.27; P  0.15). This could not be retained when it
was added to the multivariate model (P  0.56 and P 
0.42, respectively). The total number of -cells trans-
planted or the number of donors used did not affect CVfg
nor C-peptide levels.
Comparison of insulin-independent and insulin-
treated recipients in terms of posttransplant lympho-
cyte counts and immune status. One week after start of
the immune therapy, the number of CD3 cells had
markedly dropped in both groups, reaching similar low
values that were maintained until posttransplant month 6
(Fig. 1A). On the other hand, baseline CD19 counts did
not decrease during the ﬁrst week, thus remaining higher
in the patient group that did not become insulin indepen-
dent (Fig. 1A); at later time points, CD19 counts had
decreased to similar levels in both groups. Total ATG dose
in insulin-independent patients was similar to that used in
insulin-requiring patients (21.9 mg/kg body wt [IQR 20.0–
24.7] and 23.6 mg/kg body wt [22.0–26.2], respectively, P 
0.11). Mean tacrolimus trough levels (9.2 ng/ml [8.6–9.5]
and 9.2 ng/ml [7.4–9.7]) and MMF dose (2,000 mg/day
[IQR 1,500–2,000] and 2,000 mg/day IQR [1,500–2,000])
during the ﬁrst 6 months posttransplant were also compara-
ble between both groups (P  0.66 and P  0.45, respec-
tively). A similar observation was made for CVfg and mean
C-peptide levels during the ﬁrst 6 months (data not shown).
We were unable to demonstrate any correlations be-
tween posttransplant immune measures and clinical out-
come in the ﬁrst 6 months posttransplant (Table 2).
Interestingly, we observed a clear difference between sub-
jects showing T-cell reactivity posttransplant when these
results were combined with baseline T-cell reactivity. In
eight subjects where T-cell reactivity was present both at
baseline and during the ﬁrst 6 months, only one achieved
insulin independence. C-peptide levels were low in these
patients (mean 0.74 ng/ml) and CVfg high (mean 33%).
TABLE 4
Univariate and multivariate analysis of recipient characteristics associated with clinical outcome














Age (years) 0.14 0.02 0.28 0.17
Sex (male/female) 0.46 0.44 0.48
Body weight (kg) 0.72 0.91 0.95
BMI (kg/m²) 0.55 0.86 0.83
Duration of disease (years) 0.30 0.55 0.41
A1C (%) 0.05 0.71 0.48
Insulin dose (IU  kg
1  day
1) 0.13 0.02 0.22 0.04 0.17
Fasting glycemia
Mean (mg/dl) 0.65 0.70 0.11
CVfg (%) 0.42 0.78 0.94
Immune status before ATG
Total lymphocyte count 0.007 0.21 0.001 0.02 ( 0.370) 0.006 0.001 ( 0.437)
CD3 count 0.05 0.32 0.06 0.08
CD19 count 0.02 0.03 (odds ratio 0.989) 0.08 0.13
Leucocyte count 0.04 0.14 0.007 0.97 0.04 0.34
T-cell reactivity against IA2
and/or GAD 0.05 0.06 (odds ratio 0.101) 0.01 0.02 ( 0.352) 0.001 0.001 ( 0.652)
Presence of autoantibodies
pretransplant (yes/no) 0.70 0.86 0.88
Immune status at ﬁrst infusion
Total lymphocyte count 0.19 0.50 0.46
CD3 count 0.73 0.81 0.83
Leucocyte count 0.36 0.004 0.03 ( 0.363) 0.02 0.17
Immune status posttransplant
days 1–7
Median CD3 count 0.38 0.82 0.76
Median CD19 count 0.04 0.54 0.02 0.51 0.03 0.89
Median CD4-to-CD8 ratio 0.59 0.29 0.39
*Mann-Whitney U test for continuous variables, Fisher exact test for categorical data. †Independent predictor ability of the variables studied
by forward stepwise binary logistic regression analysis. ‡Pearson’s correlation for continuous variables and Mann-Whitney U test for
categorical variables. §Independent predictor ability of the variables studied by stepwise linear regression analysis, inclusion criteria P 
0.05.
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after transplantation, four achieved insulin independence
(P  0.03) with mean C-peptide levels of 1.9 ng/ml (P  0.01)
and low mean CVfg (20%; P  0.02). Among 10 recipients
with baseline T-cell autoreactivity who where negative dur-
ing the ﬁrst 6 months posttransplant, results were interme-
diate. Five reached insulin independence; C-peptide levels
were 1.1 ng/ml with CVfg 24%. Highest C-peptide levels (1.7
ng/ml) and lowest CVfg (18%) were seen in four patients who
never presented T-cell autoreativity. Three of them reached
insulin independence.
Presence of B-cells in long-term islet cell implant in
the liver of a recipient with high blood B-cell count. A
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FIG. 1. T- and B-cell count at baseline and during 6 months after transplantation (A) in islet graft recipients gaining insulin independence (solid
line) and remaining insulin independent (dotted line). Data represent means  SE; *P < 0.05. B: Gain of insulin independence according to
baseline in vitro T-cell reactivity against islet autoantigens. The lower panel shows gain of insulin independence in three different groups

























































































FIG. 2. The effect of baseline total lymphocyte count (A), in vitro T-cell reactivity against islet autoantigens or both (B) on glycemic stability and
C-peptide release.
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islets were identiﬁed in a portal tract. Endocrine cell
clusters were identiﬁed by their positivity for chromo-
granin, proinsulin, and insulin (Fig. 3). They were sur-
rounded by CD20 and CD3 cells; there were only few
CD8 cells detected. The CD20 cells were dominant in
the examined sections. The patient had not become insulin
independent, and his posttransplant month 6 mean plasma
C-peptide was low (0.62 ng/ml) and CVfg high (32%). At
baseline, he did present a cellular autoreactivity against
IA2, a high total lymphocyte count (3,393/mm
3) with a
B-cell count (536/mm
3) above the 50th percentile of the
recipient population before treatment (259 B cells/mm
3);
despite 1 year of immune suppressive treatment, the
mean B-cell count until the time of the biopsy (412/mm
3)
was still above this 50th percentile. Interestingly, we did
not observe a dominant CD20 inﬁltrate in a liverbiopsy
done in the patient who died 18 weeks posttransplant of
cerebral hemorrhage. This patient had lower numbers of
total lymphocytes (1,776/mm
3) and B-cells (188 cell/mm
3)
at baseline. Last circulating CD19 cell count was 30
cells/mm
3 and mean C-peptide level 2.2 ng/ml in the last 4
weeks before she died.
DISCUSSION
The outcome of islet cell transplantation in type 1 diabetic
recipients is variable, ranging from rapid failure to return
of insulin independence. This variation can be caused by
differences in graft and in recipient characteristics, some
of which can be anticipated such as an inadequate size
and/or viability of the donor -cell mass and some being
more difﬁcult to distinguish. We have reduced graft vari-
ability by standardizing the composition of cultured islet
cell grafts (17,20). In a series of 30 C-peptide–negative
recipients of such graft, we retrospectively searched for
possible recipient characteristics that are associated with
an inadequate outcome during the ﬁrst 6 months post-
transplantation. The present data show a correlation with
the baseline immune status at the time of the implantation.
A higher blood B-cell count was associated with an
inability to induce an insulin-independent state, as was
also the case for a baseline T-cell autoreactivity against
islet antigens, both characteristics being independent vari-
ables after multivariate analysis. A higher total lymphocyte
count and a baseline T-cell autoreactivity were correlated
with lower plasma C-peptide levels and a higher variability
in fasting blood glucose.
Of 11 patients with a baseline B-cell count p50 and a
T-cell autoreactivity, only 1 became insulin independent,
while this occurred in 7 of 8 with a B-cell count p50 and
negativity for T-cell autoreactivty. In 1 of these 10 patients
with elevated baseline immune status and inadequate graft
outcome, a biopt of the implant during posttransplant year
2 showed massive B-cell accumulations in the vicinity of
insulin-positive cell aggregates; CD3 cells were also
present but less abundant, at least in the examined sec-
tions. Throughout follow-up, this patient had maintained a
mean B-cell count above the 50th percentile of the recip-
Islet 1 - insulin Islet 2 - insulin
Islet 2 - CD3+ Islet 2 - CD20+
FIG. 3. Two islets were identiﬁed in the portal tract. Semiconsecutive sections of islet two show inﬂammatory cells located around the graft,
which are dominated by CD20 B-cells. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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genic signiﬁcance of these observations is unclear.
Interestingly, no such inﬁltrate was observed around the
graft of a patient who died 18 weeks posttransplant with a
well-functioning graft and low B-cell counts. In animal
models of diabetes, B-cells appear implicated in the de-
struction of -cells (25–29). However, their role in the
development of human disease is uncertain. That type 1
diabetes can occur in a patient with severe hereditary
B-cell deﬁciency is seen as evidence that the disease can
occur without participation of B-cells (30) but does not
exclude their involvement in other patients. In islet cell
transplantation, it is not yet clear whether B-cells play a
role through production of antibodies and/or through
antigen presentation. Islet cell autoantibodies have been
correlated to recurrence of autoimmunity and clinical
outcome (8,31–34), but this was not conﬁrmed by others
(18,20) or by the present study; we did not detect a
correlation between the presence or titer of autoantibod-
ies and the number of circulating B-cells. On the other
hand, alloantibodies can mediate rejection of organ trans-
plants and islet cell grafts have been found to induce
alloantibody formation (35–37). Alloantibodies after trans-
plantation were detected in only two recipients in the
current study, one of which became insulin independent.
Besides being a source of antibodies, B-cells can also
operate as antigen-presenting cells that activate auto-
and/or alloimmunity (38–41). This mechanism has been
proposed in rejecting kidneys with a B-cell inﬁltration
(42,43). Whether B-cells can interfere with engraftment
and/or early graft function of intraportal islet cell grafts by
one of these mechanisms cannot be concluded from the
present data. Intravenous injection of the donor cells can
nevertheless be expected to immediately subject them to
inﬂuences of circulating lymphocytes and more so to
populations that are more abundant and/or rapidly acti-
vated by -cell autoantigens. It is then also conceivable
that an early local activation of B-cells may result in their
sustained presence in the islet microenvironement as was
noticed in the biopt. To replace speculation by evidence,
an immune therapy protocol will be needed in which B-cell
depletion is achieved just before and during the ﬁrst
posttansplant weeks. In a study in nonhuman primates, Liu
et al. (44) demonstrated that B-cell–directed immunother-
apy promotes long-term islet allograft survival in nonhu-
man primates that also received T-cell–depleting ATG
antibodies and a maintenance dose of rapamycin. It would
thus be interesting to examine whether addition of ritux-
imab, which selectively targets CD20 B-cells, to our
ATG-based protocol increases the percent recipients that
become insulin independent.
Islet culture is known to help survival in rat allograft by
enriching islet isolates in endocrine cells (45), but this has
not yet been demonstrated in humans. Furthermore, islet
culture can be expected to reduce inﬂammatory and/or
immune reactivity in the implant in rodents (46). We
systematically used islet culture, and a comparative study
between freshly isolated and cultured islet cells has not
yet been possible. Therefore, we are unable to assess
whether these factors may have inﬂuenced graft survival,
but it cannot be excluded.
Our data conﬁrm in a larger cohort the previously
reported correlation between a baseline T-cell reactivity
against islet cell antigens and the failure of the implant to
induce an insulin-independent state (18). They extend this
correlation to other signs of inadequate graft function such
as low plasma C-peptide levels and a high variability in
fasting glycemia. As we previously reported, this correla-
tion is conﬁned to recipients receiving lower numbers of
-cells. The role of autoreactive T-cells in -cell destruc-
tion is well accepted (47–49). It is conceivable that the
ATG-mediated lymphopenia induces a proliferation of
autoreactive memory T-cells (50), which appear present or
more abundant at baseline in a number of patients and
might therefore predispose to a more rapid or extensive
immune destruction. Patients rejecting a pancreas trans-
plant were also found to present memory CD4 T-cells
that were speciﬁc for the islet autoantigen GAD65 (51).
Indeed, we were able to demonstrate in the current study
that in those patients where baseline T-cell autoreactivity
persisted in the ﬁrst 6 months posttransplant, clinical
outcome was very poor. Although recipients who lost
baseline-detectable T-cell reactivity after transplantation
had slightly better outcome, both are still in contrast with
the well-functioning grafts in recipients where T-cell auto-
reactivity was only detectable after transplantation.
Our data demonstrate an important predictive role for
immune measures taken at baseline, before initiation of
immunosuppression, but not for samples from the day of
islet infusion. However, we did not measure B-cell and
T-cell autoreactivity at the day of infusion. We could
therefore not fully assess the correlations between those
parameters at the day of infusion and clinical outcome,
although the available data point in the same direction.
However, it is evident that B-cells are more abundant in
insulin-dependent patients in the peritransplant period,
which, we suggest, may impair graft function via mecha-
nisms we mention above. In a severe lymphopenic envi-
ronment such as during ATG treatment, assessment of
T-cell reactivity is impossible because the frequency of
circulating lymphocytes is too low (24). Yet, T-cell auto-
reactivity remains present at a later time point, demon-
strating the insufﬁcient irradication of autoreactive T-cells,
which may be susceptible to proliferation by lymphopenia-
induced homeostatic proliferation (50).
In conclusion, this study correlates circulating charac-
teristics of the baseline immune state with the metabolic
outcome of intraportal islet cell transplants in type 1
diabetic patients. A higher number of total and of B-cell
and a T-cell reactivity against -cell antigens are associ-
ated with a lower return to insulin independence, lower
plasma C-peptide levels, and/or a higher variability in
fasting glycemia; in the one case where a liver biopt was
available (1 year after the transplant) B-cells were pre-
dominantly present around the -cell aggregates. These
data support the rationale of targeting also B-cells during
the induction phase of immune therapy.
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